[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cyclophosphamide-reduced-dose\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cyclophosphamide-reduced-dose":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100569553",false,"NCT06695741","Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia","Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy as Front-line Therapy in Patients With Severe Aplastic Anemia","hypo-CASH","Inclusion Criteria:\n\n* Subject has a diagnosis of naïve severe or very severe aplastic anemia\n* Male or female age ≥ 12 years\n* Unwilling or unable to receive allogeneic hematopoietic stem cell transplantation.\n* ECOG performance status ≤2\n* Willing and able to comply with the requirements for this study and written informed consent.\n\nExclusion Criteria:\n\n* Previously received immunosuppressive therapy \\> 4 weeks\n* Previously treated with TPO-RA \\> 4 weeks\n* Have an allergy or intolerance to anti-lymphocyte globulin, cyclosporine, herombopag or cyclophosphamide.\n* Uncontrolled fungal, bacterial, or viral infection. Hepatitis-associated aplastic anemia is allowed; hepatitis B or C infection is permitted unless it causes severe liver failure.\n* Tested positive for HIV or syphilis\n* Presence of severe liver, kidney, or heart failure, or other life-threatening comorbidities.\n* History of radiotherapy and chemotherapy for malignant solid tumors in recent 5 years\n* Combined with other serious disorders\n* Pregnant or breast-feeding patients\n* Patients considered to be ineligible for the study by the investigator for reasons other than the above.","ALL","12 Years",{"count":19,"type":20},75,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a prospective, single-center, single-arm, phase 2 study. This study aims to evaluate the efficacy and safety of anti-lymphocyte globulin plus herombopag in combination with the reduced dose of cyclophosphamide (hypo-CASH) for severe aplastic anemia.",[26,27,28],"Severe Aplastic Anemia","Cyclophosphamide Reduced-dose","Immunosuppressive Therapy","RECRUITING","2024-11-16",{"date":32,"type":33},"2024-11-19","ACTUAL",{"date":35,"type":33},"2024-11-01",{"date":37,"type":20},"2027-06-30",{"name":39,"class":40},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",""]